Skip to main content

Table 1 Patient characteristics by grade of MTX adherence divided by MMAS-8 (n = 165)

From: Adherence to methotrexate and associated factors considering social desirability in patients with rheumatoid arthritis: a multicenter cross-sectional study

 

All

(n = 165)

MMAS-8

p value

Low

(n = 20)

Medium

(n = 99)

High

(n = 46)

Age, median (IQR)

64

(54–72)

58

(44–62)

65

(53–73)

65.5

(59–74)

0.01

Female, n (%)

142 (86.1)

18 (90.0)

84 (84.6)

38 (82.6)

0.74

MTX dose (mg/week), median (IQR)

8 (6–12)

10 (8–12)

8 (6–10)

10 (8–12)

0.17

MTX dosing frequency (times/week), median (IQR)

3 (2–3)

3 (2–3)

2 (2–3)

2 (2–3)

0.54

Duration of MTX treatment

(month), median (IQR)

36 (17–75)

32 (16–79)

35 (18–80)

41 (13–74)

0.15

Disease duration

(month), median (IQR)

53.5

(22.5–123.5)

35

(22–120)

47

(22–111)

60.5

(24–158)

0.95

Concomitant medication

NSAIDS, n (%)

59 (35.8)

5 (25.0)

36 (36.4)

8 (39.1)

0.53

Corticosteroid, n (%)

27 (16.4)

2 (10.0)

17 (17.2)

8 (17.4)

0.71

Biologics, n (%)

48 (29.1)

7 (35.0)

28 (28.3)

13 (28.3)

0.83

DAS28-ESR, median (IQR)

2.30

(1.68–3.00)

2.01

(1.37–2.23)

2.32

(1.68–3.02)

2.40

(2.01–3.15)

0.08

mHAQ, median (IQR)

0

(0–0.13)

0

(0–0.25)

0

(0–0)

0.13

(0–0.38)

0.02

BMQ necessity-concern differential, median (IQR)

1 (0–3)

2 (0–3)

1 (0–3)

2 (0–3)

0.81

CES-D (total score ≥ 16), n (%)

37 (26.4)

8 (47.1)

21 (8.3)

8 (20.0)

0.10

BPI (average NRS pain score), median (IQR)

2 (1–3)

1 (1–4)

1 (1–3)

1 (3–4)

0.13

SDS, median (IQR)

6 (4–7)

4 (3–6)

6 (4–6)

6.5 (5–8)

0.00

SF-8 (PCS), median (IQR)

48.1

(42.4–52.1)

47.4

(45.8–52.1)

49.8

(43.5–52.1)

45.6

(40.2–50.2)

0.04

SF-8 (MCS), median (IQR)

50.2

(45.6–54.1)

47.7

(43.0–53.2)

50.3

(46.3–53.9)

50.0

(46.1–55.0)

0.36

Marital status (married), n (%)

95 (57.9)

11 (55.0)

61 (62.2)

23 (50.0)

0.37

Educational level (greater than or equal to college level), n (%)

36 (21.8)

5 (25.0)

17 (17.2)

14 (30.4)

0.19

Employment status (full-time), n (%)

38 (23.0)

12 (60.0)

22 (22.2)

4 (8.7)

0.00

Living status (living alone), n (%)

43 (26.4)

7 (35.0)

24 (24.5)

12 (26.7)

0.62

  1. IQR interquartile range; DAS28-ESR Disease Activity Score (28 joint count)- erythrocyte sedimentation rate; mHAQ modified Health Assessment Questionnaire; BMQ Beliefs about Medicines Questionnaire; CES-D Center for Epidemiological Studies Depression; BPI Brief Pain Inventory; NRS Numerical Rating Scale; SDS Social Desirability Scale; SF-8 8-item Short-Form Health Survey; PCS physical component summary; MCS mental component summary; MTX methotrexate; MMAS-8 Morisky Medication Adherence Scale